Steroid-Resistant Graves’ Orbitopathy – therapeutic options
Ustanova
Clinic of Endocrinology, Diabetes and Metabolic Disease, University Clinical Center of Serbia
Faculty of Medicine, University of Belgrade
Reference
Bartalena L, Piantanida E, Gallo D, Lai A, Tanda ML. Epidemiology, Natural History, Risk Factors, and Prevention of Graves’ Orbitopathy. Front Endocrinol (Lausanne). 2020; 11: 1.
Men CJ, Kossler AL, Wester ST. Updates on the understanding and management of thyroid eye disease. Ther Adv Ophthalmol 2021; 13: 1–14. Kortokorezistentna Grejvsova orbitopatija – terapijske opcije 83
Tsui S, Naik V, Hoa N, Hwang CJ, Afifiyan NF, Sinha Hikim A, Gianoukakis AG, Douglas RS, Smith TJ. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves’ dis
Sažetak
Steroid-Resistant Graves’ Orbitopathy – therapeutic options
Ključne reči
Medicinski glasnik